Wealth Enhancement Trust Services’s Harmony Biosciences HRMY Stock Holding History

Wealth Enhancement Trust Services’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.62K	Buy	+72	New	+$2.27K	﹤0.01%	957

Other funds holding HRMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Wealth Enhancement Trust Services's HRMY Position: Q2 2026 in Review

Wealth Enhancement Trust Services opened a new position in Harmony Biosciences (HRMY) in Q2 2026: 72 shares worth $2.62K. The stake represents ﹤0.01% of the portfolio and ranks #957 among its holdings.

213 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

Wealth Enhancement Trust Services held 72 shares of Harmony Biosciences worth $2.62K as of Q2 2026.
Harmony Biosciences was a new Wealth Enhancement Trust Services position in Q2 2026.
Harmony Biosciences made up ﹤0.01% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #957 holding.
213 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.